Aditum Bio Announces Formation of Third Company, Anteris Bio

OAKLAND, Calif., Dec. 15, 2020 /PRNewswire/ -- Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, today announced the formation of Anteris Bio, a portfolio company developing a new therapy for the treatment of renal disease. Anteris Bio is being formed following the successful in-licensing of ANT-401 from vTv Therapeutics (NASDAQ:VTVT).   

Anteris Bio is the third independent company launched by Aditum Bio, whose mission is to give large patient populations access to medicines which otherwise may not be developed. To speed these drugs to market, Aditum Bio fosters an incubator model, focusing on the translational phase of drug development. The "spin out" model enables a nimble, start-up culture with its own dedicated team of managers.

"We are excited to announce the formation of Anteris Bio, with its focus on renal disease. Unmet medical need is high, with few therapies in development that have the potential to be disease modifying," said Joe Jimenez, Co-Founder and Managing Director of Aditum Bio. Dr. Mark Fishman, Co-Founder and Chair of the Medical and Scientific Advisory Boards added, "The relentless progression of renal disease has been largely refractory to medical therapies.  We hope the fundamental mechanism exemplified by ANT-401 will change that for the better." 

Chronic kidney disease (CKD) is one of the most significant global health challenges and a leading cause of mortality, both directly and as a key risk factor for cardiovascular disease. Globally, it is estimated that nearly 700 million individuals suffer from CKD, and CKD is directly responsible for over 1 million deaths annually. Clear unmet medical need exists in renal disease as therapies have traditionally revolved around treatment of symptoms (e.g. hypertension, renal failure). ANT-401 is a small molecule activator of Nrf2, a mechanism which has disease modifying potential across multiple etiologies of renal disease. Nrf2 is a transcription factor required for the expression of many antioxidant genes regulated by the ARE promoter sequence. ANT-401 activates Nrf2 through the inhibition of Bach1, a transcription repressor that prevents Nrf2 activity in the nucleus.

Aditum Bio has partnered with TrialSpark, a technology driven research company that can complete clinical trials faster and at a lower cost than traditional trials. TrialSpark partners with doctors to create trial and referral sites within their existing practices. Their digital platform enables faster patient recruitment, together with common data entry and analysis across sites which leads to speed, quality, and standardization.

About Aditum Bio
Aditum Bio is committed to improving public health by accelerating R&D in disease areas with both large and more targeted patient populations, where medical innovation can have a huge impact. Aditum Bio focuses on basic mechanisms of disease, in-licenses promising drug candidates directed at such pathophysiologies, and spins-out individual companies dedicated to bringing each candidate through Phase II clinical trials. In partnership with TrialSpark, Aditum Bio uses data, software and technology to help bring innovative medicines through the clinical trial phase more quickly and with lower costs than traditional pharmaceutical companies.

For more information, please visit www.aditumbio.com.

About TrialSpark
TrialSpark is a technology company that runs end-to-end clinical trials as an alternative to a traditional CRO. TrialSpark has built a technology platform that optimizes all aspects of a clinical trial, enabling faster trial completion, higher data quality, and a more patient-centric experience. TrialSpark also empowers doctors in the community setting to participate in clinical trials, unlocking the 99% of patients the industry has traditionally struggled to reach, accelerating recruitment rates, and democratizing access to clinical trials. TrialSpark is backed by leading investors such as Michael Moritz, John Doerr, Thrive Capital, and Sequoia Capital.

About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer's disease, and inflammatory disorders. vTv's development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), and genetic mitochondrial diseases. For more information, please visit www.vtvtherapeutics.com or follow us on Twitter: @vTvTherapeutics.

Media
For inquiries, please contact:
Susie Phillips
Aditum Bio
(510) 227-2096
[email protected]

SOURCE Aditum Bio

Related Links

https://www.aditumbio.com